14-day Premium Trial Subscription Try For FreeTry Free
DBV Technologies (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Friday, Zacks.com reports. According to Zacks, DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The []

Why DBV Technologies Stock Is Jumping Today

12:33pm, Monday, 01'st Nov 2021
The company plans to announce new data for its experimental peanut allergy drug this week.
DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
DBV Technologies (NASDAQ: DBVT) has received communication from the FDA concerning the STAMP protocol submission for its modified Viaskin Peanut (mVP) development program. The agency would like to
Montrouge, France, August 31, 2021
AMF REGULATED INFORMATION Montrouge, France, August 6, 2021
DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q2 2021 Results - Earnings Call Transcript
Montrouge, France, June 2, 2021
Montrouge, France, May 5, 2021
Montrouge, France, May 3, 2021
Montrouge, France, April 29, 2021
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE